Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine

Journal of Immunology

Volumn 163, Issue 3, 1999, Pages 1690-1695

  Rosenberg, Steven A ^a,b   Yang, James C ^a   Schwartzentruber, Douglas J ^a   Hwu, Patrick ^a   Marincola, Francesco M ^a   Topalian, Suzanne L ^a   Restifo, Nicholas P ^a   Sznol, Mario ^a   Schwarz, Susan L ^a   Spiess, Paul J ^a   Wunderlich, John R ^a   Seipp, Claudia A ^a   Einhorn, Jan H ^a   Rogers Freezer, Linda ^a   White, Donald E ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 12; SYNTHETIC PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; METASTASIS; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VACCINATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL LINE; CYTOKINES; FREUND'S ADJUVANT; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; LIPIDS; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; STEM CELLS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0033178581     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rosenberg, S. A. 1996. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88:1635.
2. Van Pel, A., P. Van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethe, B. Van Den Eynde, C. Uyttenhove, J.-C. Renauld, and T. Boo. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229.
3. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N. Engl. J. Med. 319:1676.
4. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, and D. E. White. 1994. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J. Natl. Cancer Inst. 86: 1159.
5. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
6. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. R. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
7. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
8. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
9. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0210 binding residues. J. Immunol. 157:2539.
10. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
11. Bronte, V., K. Tsung, J. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N. P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154: 5282.
12. Chen, P. W., M. Wang, V. Bronte, Y. Zhai, S. A. Rosenberg, and N. P. Restifo. 1996. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156:224.
13. Irvine, K. R., R. B. Rao, S. A. Rosenberg, and N. P. Restifo. 1996. Cytokine enhancement of DNA immunization leads to treatment of established pulmonary metastases. J. Immunol. 156:238.
14. Noguchi, Y., E. C. Richards, Y. T. Chen, and L. J. Old. 1995. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92:2219.
15. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colon-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
16. Jaeger, E., M. Ringhoffer, H. P. Dienes, M. Arand, J. Karbach, D. Jager, C. Ilsemann, M. Hagedorn, F. Oesch, and A. Knuth. 1996. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer 67:54.
17. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J. Am. Med. Assoc. 271:907.
18. Schwartz, R. H. 1997. T cell clonal anergy. Curr. Opin. Immunol. 3:351.
19. Lenardo, M. J. 1991. Interleukin-2 programs mouse αB T lymphocytes for apoptosis. Nature 353:858.
20. Welsh, R. M., L. K. Selin, E. S. Razvi. 1995. Role of apoptosis in the regulation of virus-induced T cell responses, immune suppression, and memory. J. Cell. Biochem. 59:135.